1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Syndax’s Revumenib Makes Splash At ASH As Company Eyes Blockbuster Opportunity

 
• By Alaric DeArment

The company presented data for the menin inhibitor in KMT2Ar acute leukemias in an ASH late-breaker. The larger addressable population, including mNPM1 AML, could be a $2bn opportunity.

• Source: Scrip

Syndax Pharmaceuticals, Inc. is starting out with a rare subset of acute leukemia patients when it submits revumenib for US Food and Drug Administration review at the end of the year, but it is also aiming for a larger subset that could potentially yield a blockbuster opportunity, one in which others hope to compete as well.

Key Takeaways

  • Syndax presented data from the pivotal Phase II AUGMENT-101 trial of revumenib in KMT2Ar acute myeloid leukemia and acute lymphoid leukemia at the ASH late-breaking abstract session.

  • The data showed a significant improvement in response rates and overall survival for a patient population with a historically poor prognosis

The company presented results from the pivotal Phase II AUGMENT-101 trial in a late-breaking abstract at the American Society of Hematology annual meeting in San Diego on 12 December for the drug, a menin inhibitor, in adult and pediatric acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) patients with KMT2A rearrangements (KMT2Ar)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Conferences

Balance And Focus Suggested For Globalizing Chinese Firms Amid Ongoing Uncertainties

 
• By Xu Hu

Finding a balance between out-licensing, refocusing on internal strengths and addressing unmet needs were identified at a recent Shanghai conference as some of the key strategies for Chinese biopharma firms looking to truly globalize.

Cash-Strapped Chinese Biotechs A Growing Draw For Western Pharma Partnering

 
• By Alaric DeArment

Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.

Lexicon Has A Lot Riding On LX9211 Phase IIb Readout In Pain

 
• By Jessica Merrill

CEO Mike Exton talked to Scrip about moving the company forward after a disappointingly disruptive 2024.